A new chapter is opening in cancer immunotherapy. A first-in-human clinical trial of CRISPR technology to treat late stage lung cancer has proved safe by a CUHK joint research. T-Cells of advanced condition patients have been extracted, gene edited and reinfused as potential fighters against cancer cells.